SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-007286
Filing Date
2020-05-11
Accepted
2020-05-11 06:21:55
Documents
53
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20200331.htm   iXBRL 10-Q 1351453
2 EX-31.1 oyst-q1x20ex311.htm EX-31.1 15227
3 EX-31.2 oyst-q1x20ex312.htm EX-31.2 15576
4 EX-32.1 oyst-q1x20ex321.htm EX-32.1 10268
5 EX-32.2 oyst-q1x20ex322.htm EX-32.2 10263
  Complete submission text file 0001628280-20-007286.txt   4834049

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20200331.xsd EX-101.SCH 28848
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20200331_cal.xml EX-101.CAL 73682
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20200331_def.xml EX-101.DEF 107611
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20200331_lab.xml EX-101.LAB 391506
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20200331_pre.xml EX-101.PRE 248385
48 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20200331_htm.xml XML 716782
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 20862498
SIC: 2836 Biological Products, (No Diagnostic Substances)